Cipla Ltd., through its UK unit, Cipla EU, inked agreements to acquire the U.S.-based generics company, Invagen Pharmaceuticals Inc., and consulting firm Exelan Pharmaceuticals Inc., in an all-cash deal valued at $550 million. The move represented the second big shift in the U.S. generics market in as many days, coming 24 hours after Lannett Co. Inc., of Philadelphia, said it was purchasing Kremers Urban Pharmaceuticals Inc., of Princeton, N.J. – the U.S. specialty generic pharmaceuticals subsidiary of UCB SA, of Brussels – for $1.23 billion up front and undisclosed contingency payments. Read More
TOKYO – Domestic and multinational pharmaceutical companies want Japan to maintain a scheme that adds price premiums to certain drugs, which makes it easier for drug companies to recoup research and development costs. Read More
TOKYO – Japan is reaching out to drugmakers and developers from Asia and elsewhere, looking to attract more innovative products and emerge as a regional leader in the field. Read More
Santen Pharmaceutical Co. Ltd., of Osaka, Japan, opened new European headquarters in Geneva. That facility will lead the firm’s commercial network, manufacturing and R&D activities. Read More
